A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

ClinicalTrials.gov ID: NCT05890729

Public ClinicalTrials.gov record NCT05890729. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Seamless, Phase 1b/2 Multiple Ascending Dose/Proof of Concept Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations

Study identification

NCT ID: NCT05890729
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Xentria, Inc.; Industry
Enrollment: 94 participants

Conditions and interventions

Conditions

Pulmonary Sarcoidosis

Interventions

XTMAB-16 or Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 9, 2023
Primary completion: Apr 30, 2029
Completion: Apr 30, 2029
Last update posted: May 19, 2026

2023 – 2029

United States locations

U.S. sites: 17
U.S. states: 15
U.S. cities: 16

Facility	City	State	ZIP	Site status
Xentria Investigative Site	Birmingham	Alabama	35233	Recruiting
Xentria Investigative Site	Denver	Colorado	80206	Recruiting
Xentria Investigative Site	Jacksonville	Florida	32209	Completed
Xentria Investigative Site	Chicago	Illinois	60611	Recruiting
Xentria Investigative Site	Chicago	Illinois	60612	Recruiting
Xentria Investigative Site	Iowa City	Iowa	52242	Recruiting
Xentria Investigative Site	Baltimore	Maryland	21287	Recruiting
Xentria Investigative Site	Detroit	Michigan	48202	Recruiting
Xentria Investigative Site	Minneapolis	Minnesota	55455	Recruiting
Xentria Investigative Site	Albany	New York	12208	Terminated
Xentria Investigative Site	New York	New York	10029	Recruiting
Xentria Investigative Site	Greenville	North Carolina	27858	Recruiting
Xentria Investigative Site	Cincinnati	Ohio	45267	Recruiting
Xentria Investigative Site	Philadelphia	Pennsylvania	19140	Recruiting
Xentria Investigative Site	Charleston	South Carolina	29425	Recruiting
Xentria Investigative Site	Houston	Texas	77030	Withdrawn
Xentria Investigative Site	Charlottesville	Virginia	22903	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05890729, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 19, 2026 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05890729 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →